Sunday, June 05, 2022 9:59:10 AM
Unity Biotechnology (UBX) Receives a Buy from Mizuho Securities
Source: TipRanks
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $7.00. The company's shares closed last Thursday at $0.77, close to its 52-week low of $0.70. According to TipRanks.com, Syed 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.5% and a 34.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences. Currently, the analyst consensus on Unity Biotechnology is a Strong Buy with an average price target of $7.00.
Recent UBX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:05:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:05:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/11/2023 05:15:29 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/08/2023 09:39:06 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/06/2023 10:25:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 12:00:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 08:05:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 11:05:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/15/2023 08:08:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/15/2023 08:07:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 08:05:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:07:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:04:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2023 08:13:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/03/2023 08:13:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2023 08:05:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2023 08:04:47 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM